It's been a volatile stretch for two of the most closely watched ASX stocks.
Pro Medicus Ltd (ASX: PME) surged 8% on Thursday, extending its five-day gain to 22%, while Aristocrat Leisure Ltd (ASX: ALL) added another 3%.
Yet despite the recent bounce, both remain firmly in the red for the year. Pro Medicus is still down around 33%, while Aristocrat has slipped 15%.
Hectic? Absolutely. But for long-term investors, the bigger question is simple: has the market created opportunity in two high-quality operators?
Let's break it down.
Image source: Getty Images
Pro Medicus: high-margin healthcare tech with global reach
This ASX healthcare stock sits in a rare category on the ASX — a pure-play, high-margin healthcare technology company with global scale.
Its flagship Visage platform is used by major hospitals and medical institutions to rapidly process and interpret medical imaging. That might sound niche, but it's exactly this focus that has created its competitive advantage.
High switching costs, long contracts, and deep integration into hospital systems make its revenue base sticky and highly scalable. Once embedded, customers rarely leave.
Despite recent volatility, analysts remain constructive. Bell Potter just retained its buy rating on Pro Medicus, albeit with a slightly reduced price target of $226 (from $240). At current levels around $148.88, that implies potential upside of roughly 52% over the next 12 months.
Of course, risks remain. Valuation sensitivity is high, and any slowdown in contract wins or hospital spending could quickly weigh on sentiment. But the long-term growth story — driven by digitisation of healthcare — remains firmly intact.
Aristocrat: gaming dominance with global scale
Aristocrat Leisure Ltd is another ASX heavyweight that has found itself under pressure this year.
But beneath the share price volatility, the core business continues to deliver.
Aristocrat generates strong earnings from gaming machines, digital gaming content, and its fast-growing online segment, particularly in the US. That mix gives it exposure to both traditional casino demand and the structural growth of digital entertainment.
Importantly, underlying demand trends in US gaming remain resilient, even as sentiment has cooled.
Macquarie remains bullish on the ASX stock. The broker has maintained its outperform rating and set a $63.00 price target, implying potential upside of around 28% from current levels.
In other words, the market may be underestimating the strength and consistency of Aristocrat's earnings engine.
There are risks, of course. Gaming is cyclical, regulation can shift, and consumer spending can fluctuate. But Aristocrat's scale, content pipeline, and global footprint help cushion those swings.
Foolish Takeaway
Both Pro Medicus and Aristocrat have been hit by volatility this year. But neither ASX stock has lost its competitive edge.
For investors willing to look beyond short-term noise, these two ASX leaders still offer something rare: high-quality businesses trading in less-than-perfect sentiment. And that's often where long-term opportunities begin.
